Portal de Periódicos da CAPES

Correction: Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

2016; Nature Portfolio; Volume: 7; Issue: 1 Linguagem: Inglês

10.1038/ncomms13513

2041-1723

Jacob J. Chabon, Andrew D. Simmons, Alexander F. Lovejoy, Mohammad Shahrokh Esfahani, Aaron M. Newman, Henry J. Haringsma, David M. Kurtz, Henning Stehr, Florian Scherer, Chris Karlovich, Thomas C. Harding, Kathleen A. Durkin, Gregory A. Otterson, W. Thomas Purcell, D. Ross Camidge, Jonathan W. Goldman, Lecia V. Sequist, Zofia Piotrowska, Heather A. Wakelee, Joel W. Neal, Ash A. Alizadeh, Maximilian Diehn,

Lung Cancer Treatments and Mutations

Nature Communications 7: Article number: 11815 (2016); Published 10 June 2016; Updated 14 November 2016 Previous work by Del Re et al. describing the emergence of KRAS mutations following treatment of non-small cell lung cancer patients with EGFR tyrosine kinase inhibitors was inadvertently omitted from the reference list of this Article and should have been cited as follows.